Home › Companies › SMMT

Pipeline (3 active programs)

Discontinued (1)

• ivonescimab — Clear Cell Renal Cell Carcinoma · not a Summit-sponsored program — Arcus conducts and sponsors the casdatifan+ivonescimab ccRCC cohort in its ARC-20 platform study; Summit only supplies drug and co-funds (collaborator, not sponsor)

Biotech Distilled coverage (10)

• 2026-07-22 UPDATE: Summit Therapeutics (SMMT) - The Western OS Number Just Caught Up
• 2026-06-11 UPDATE: Summit Therapeutics (SMMT) - The Deal Got Pulled
• 2026-06-09 UPDATE: Summit Therapeutics (SMMT) - The $500M Bait-and-Switch
• 2026-06-03 UPDATE: Summit Therapeutics (SMMT) - The Insiders Got the Green Light
• 2026-06-02 UPDATE: Summit Therapeutics (SMMT) - The Plenary Delivered. The Tape Didn’t. 🔒 Paid
• 2026-05-02 UPDATE: Summit Therapeutics (SMMT) - The 25% Panic Into ASCO 🔒 Paid
• 2026-05-01 UPDATE: Summit Therapeutics (SMMT) - Q1 2026 Earnings, an iDMC Pass, and an ASCO Plenary Slot 🔒 Paid
• 2026-03-29 UPDATE: Summit Therapeutics (SMMT) - ELCC 2026 Data 🔒 Paid
• 2026-03-01 UPDATE: Summit Therapeutics (SMMT) - EoY 2025 Update 🔒 Paid
• 2026-02-20 Summit Therapeutics (SMMT): Scientific Deep Dive for Ivonescimab and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.